- Home
- KRP vs PVLA Comparison
KRP vs PVLA Comparison
Compare KRP & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KRP | PVLA |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | KRP | PVLA |
|---|---|---|
| Price | $12.56 | $104.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 17 |
| Target Price | $17.00 | ★ $145.24 |
| AVG Volume (30 Days) | ★ 833.3K | 318.6K |
| Earning Date | 02-26-2026 | 11-11-2025 |
| Dividend Yield | ★ 13.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $315,520,668.00 | N/A |
| Revenue This Year | $7.04 | N/A |
| Revenue Next Year | $0.92 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.98 | $12.02 |
| 52 Week High | $16.21 | $114.69 |
Technical Indicators
Market Signals| Indicator | KRP | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 55.55 |
| Support Level | $11.42 | $90.85 |
| Resistance Level | $12.16 | $105.68 |
| Average True Range (ATR) | 0.31 | 8.26 |
| MACD | 0.14 | -0.06 |
| Stochastic Oscillator | 89.47 | 84.80 |
Price Performance
Historical ComparisonAbout KRP Kimbell Royalty Partners
Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.